|

NPX887 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • NextPoint Therapeutics, Inc.1

Indications

  • Metastatic Malignant Neoplasm1
  • Cancer1

Baltimore, Maryland1 trial

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.